These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24915266)

  • 21. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes costs rise, but so does adherence.
    Manag Care; 2005 Apr; 14(4):54. PubMed ID: 15898213
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses.
    Rodbard HW; Green AJ; Fox KM; Grandy S;
    Diabetes Res Clin Pract; 2010 Mar; 87(3):360-5. PubMed ID: 20047768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Devices in Insulin Delivery.
    Meneghini LF; McNulty JN
    Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
    [No Abstract]   [Full Text] [Related]  

  • 25. Predictors of direct costs of diabetes care in pediatric patients with type 1 diabetes.
    Ying AK; Lairson DR; Giardino AP; Bondy ML; Zaheer I; Haymond MW; Heptulla RA
    Pediatr Diabetes; 2011 May; 12(3 Pt 1):177-82. PubMed ID: 20807368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
    Luo J; Feldman R; Rothenberger SD; Hernandez I; Gellad WF
    JAMA Netw Open; 2020 Oct; 3(10):e2020969. PubMed ID: 33057641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Are the short-acting insulin analogs superfluous?].
    Arand M
    MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of insulin pen devices on the management of diabetes mellitus.
    Meece J
    Am J Health Syst Pharm; 2008 Jun; 65(11):1076-82. PubMed ID: 18499883
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
    Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
    J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?
    English P
    Br J Hosp Med (Lond); 2013 Apr; 74(4):192-7. PubMed ID: 23571388
    [No Abstract]   [Full Text] [Related]  

  • 33. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes.
    Kleinman NL; Schaneman JL; Lynch WD
    J Occup Environ Med; 2008 Dec; 50(12):1386-93. PubMed ID: 19092494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs Associated With Using Different Insulin Preparations.
    Tylee T; Hirsch IB
    JAMA; 2015 Aug; 314(7):665-6. PubMed ID: 26284715
    [No Abstract]   [Full Text] [Related]  

  • 35. The persistent complication of hypoglycemia in diabetics.
    Dangi-Garimella S
    Am J Manag Care; 2014 May; 20(8 Spec No.):E17. PubMed ID: 25617934
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
    J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
    Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
    Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
    Hess R; Kerner W
    Dtsch Med Wochenschr; 2006 Oct; Suppl 1():36-7. PubMed ID: 17595817
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes.
    Brown RR
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S24-7. PubMed ID: 9872692
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.
    Śliwczyński A; Brzozowska M; Jacyna A; Iltchev P; Iwańczuk T; Wierzba W; Marczak M; Orlewska K; Szymański P; Orlewska E
    PLoS One; 2017; 12(6):e0178764. PubMed ID: 28582404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.